Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against Baxter International, Inc. and certain executives, alleging misleading statements regarding the safety and efficacy of the Novum IQ Large Volume Pump, which has been linked to serious patient risks [1][2][4]. Company Overview - Baxter International, Inc. is a global healthcare company that develops and sells medical products for hospitals and healthcare facilities. The company recently launched the Novum IQ Large Volume Pump, which is intended for intravenous fluid delivery [2]. Allegations in the Lawsuit - The lawsuit claims that Baxter and its executives misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not adequately address these issues [2]. - The lawsuit also states that Baxter's communications regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Timeline of Events - Safety concerns regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion issues. Baxter issued warning letters to customers about potential risks shortly thereafter [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in the company's stock price [4]. Class Action Details - Individuals who purchased Baxter common stock during the specified class period may seek appointment as Lead Plaintiff in the lawsuit, with a deadline for filing motions set for December 15, 2025 [5].

Core Insights - Tactile Systems Technology, Inc. (TCMD) specializes in developing medical devices for chronic diseases, particularly lymphedema, within the resilient healthcare sector [1] - TCMD has experienced a strong monthly gain of approximately 7.23%, indicating positive investor sentiment and confidence in the company's future prospects [2][6] - Despite a recent 10-day decline of about 3.36%, TCMD's overall trajectory remains positive, presenting potential buying opportunities for investors [3] - The projected growth potential for TCMD is 27.64%, suggesting a target price of $18.75, supported by continuous demand and innovation in the healthcare sector [4] - TCMD's strong Piotroski Score of 8 reflects its robust financial health, indicating profitability, leverage, liquidity, and operational efficiency [5][6]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized s ...

Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market ope ...

ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced it will be featured in multiple Live Learning Sessions at Booth #2931 during the American Academy of Ophthalmology Annual Meeting (AAO 2025), taking place October 18–20 at the Orange County Convention Center in Orlando, Fla. This year’s Live Learning Sessions showcase real-world ...

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Semler Scientific, Inc. (NASDAQ: SMLR). Shareholders who purchased shares of SMLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/semler-scientific-inc-loss-submission-form/?id=172062&from=3  CLASS PERIOD ...

Key Takeaways J&J plans to separate its Orthopaedics franchise to form a standalone company named DePuy Synthes.The move aligns with J&J's strategy to emphasize high-growth MedTech markets.J&J expects the spin-off to lift MedTech revenue growth and margins.Along with its third-quarter earnings release on Oct. 14, Johnson & Johnson (JNJ) announced its intention to separate its Orthopaedics franchise within the MedTech segment.J&J plans to spin off the Orthopaedics franchise as a standalone company. The compa ...

Summary of Perimeter Medical Imaging AI Conference Call Company Overview - **Company**: Perimeter Medical Imaging AI - **Ticker Symbols**: OTCQX: PYNKF, TSXV: PINK - **Industry**: Medical Imaging Technology, specifically focused on cancer surgery Core Issues Addressed - **Problem Statement**: High rates of reoperations in cancer surgeries due to incomplete removal of cancerous tissues, leading to emotional and financial burdens on patients, hospitals, and insurers [4][10][12] - **Statistics**: - Breast cancer reoperation rate: 23% - Thyroid cancer reoperation rate: 12% - Prostate cancer reoperation rate: 21% [6][7] Technology and Solutions - **Imaging Technology**: Optical Coherence Tomography (OCT) provides high-resolution imaging (10x better than X-ray, 100x better than MRI) to visualize cancerous cells in real-time during surgery [13][14] - **Device Description**: The imaging system allows surgeons to see cellular-level details and make informed decisions during surgery, potentially reducing reoperation rates [16][22] - **AI Integration**: Future products will incorporate AI algorithms to assist surgeons by highlighting suspicious areas in real-time, thus improving efficiency and accuracy [20][26][28] Market Opportunity - **Total Addressable Market (TAM)**: Estimated at $17 billion globally, with a U.S. market of $4 billion and a specific breast cancer surgery market of $650 million [36][37] - **Annual Healthcare Costs**: Over $1 billion in healthcare costs due to re-excisions, not including emotional costs and survival rates [32][33] Clinical Results and Performance - **Clinical Trials**: Successful trials with major cancer institutions, showing significant improvements in reoperation rates [31][40] - **Surgeon Feedback**: Surgeons using the technology reported reoperation rates dropping from 20% to around 5% [39][41] Financial Performance - **Revenue Growth**: Revenue increased from a few hundred thousand to over half a million per quarter, primarily driven by high-margin recurring revenue from consumables [43][44] - **Gross Margin**: Approximately 90% gross margin on consumables, indicating a strong business model [44] Competitive Advantages - **Intellectual Property**: Strong patent protection around imaging technology and proprietary algorithms, making it difficult for competitors to replicate [47] - **Market Demand**: Surgeons are driving demand for the technology, leading to increased adoption and market share [38][42] Future Outlook - **Regulatory Approval**: The AI-enabled device is undergoing FDA approval, expected to be on the market by Q2 of the following year [55][56] - **Growth Strategy**: Focus on expanding market presence and increasing the number of devices in use to drive consumable sales [57] Leadership Team - **Key Members**: - Adrian Mendes, CEO - Sarah O'Brien, CFO - Dr. Ted James, Chief Medical Officer [49][50] Conclusion - Perimeter Medical Imaging AI is positioned to significantly impact cancer surgery outcomes through innovative imaging technology and AI integration, with a strong market opportunity and a solid growth trajectory ahead [51][58]

Startup Leo Cancer Care is transforming proton radiation treatment with a simple idea: having patients sit up instead of lying down. Now hospitals that include Stanford and McLaren are lining up to buy dozens of machines. https://t.co/j6wkzeExmH (Photos: Leo Cancer Care) https://t.co/wWyx4zdBPz ...

We are exiting our position in Abbott Laboratories , selling 250 shares at roughly $129. Following the trade, Jim Cramer's Charitable Trust will no longer hold a position in Abbott. Abbott Labs reported a mixed quarter on Wednesday as strength in its medical devices business was partially offset by softness in its nutrition and diagnostics units. For such a high-quality company with a long track record of beating analyst estimates and raising its full-year outlook, this was the second consecutive quarter wh ...